Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA. In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury. Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company has received approval from the FDA to conduct a Phase Ib safety trial evaluating NSI-189, its first small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder.
View Top Employees from Neuralstem, Inc.Website | http://www.neuralstem.com/ |
Ticker | CUR |
Revenue | $260000 |
Funding | $16.3 million |
Employees | 7 (5 on RocketReach) |
Founded | 1996 |
Address | 20271 Goldenrod Ln. Ste. 2024, Germantown, Maryland 20876, US |
Phone | (301) 366-4841 |
Technologies |
JavaScript,
HTML,
Google Analytics
+20 more
(view full list)
|
Industry | Biotechnology, Pharmaceuticals, Healthcare, Science and Engineering, Neuroscience, Drug Manufacturing & Research, Therapeutics, Health Care |
Web Rank | 2 Million |
Keywords | Neuralstem, Que Es El Nsi-566, Without Giving Effect To 适用法律, Neuralstem Initiates Program To Expand Its Current Pipeline Of Therapeutic Products, Neural Stem Stock |
Competitors | Acadia Pharmaceuticals Inc., Brainstorm Cell Therapeutics, Neuronascent, Inc, Semma Therapeutics |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 541 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies |
Looking for a particular Neuralstem, Inc. employee's phone or email?
The Neuralstem, Inc. annual revenue was $260000 in 2024.
5 people are employed at Neuralstem, Inc..
Neuralstem, Inc. is based in Germantown, Maryland.
The NAICS codes for Neuralstem, Inc. are [5417, 54, 32541, 32, 541, 325, 3254].
The SIC codes for Neuralstem, Inc. are [28, 283].